Centralization of genomics-bioinformatics will provide the SPORE investigators with access to the state-of- the-art genomic capability and bioinformatics expertise, by leveraging existing institutional infrastructure such as Harvard/Partners Center for Genomics and Genetics and the Belfer Cancer Genomics Center. An important benefit derived from centralization comes from improved data storage and sharing, allowing for better integration of ideas and information across the various projects within the SPORE. Moreover, given the pace of discovery in areas of genomics and bioinformatics, it is difficult to predict where the field will stand even one year in advance. This invariant feature of change provides justification for a core with strong technical implementation capability and intellectual leadership throughout the granting period, so that the best technology will be brought to bear on the biological questions of the SPORE. This Core will provide several levels of support to the SPORE. First, it will offer bioinformatics consultation, in collaboration with Biostatistics, to assist all projects in the design and preliminary analyses of genomic studies, including copy number and expression profiling as well as gene re-sequencing. In this process, the Core will serve the central coordinating role in data receipt/storage for genomic assays in all projects, so that integrated analyses can be performed more easily. Second, the Core will leverage existing institutional infrastructure for established capabilities such as expression profiling and candidate gene re-sequencing. In addition, the Core will bring to the SPORE unique capability in high-resolution copy number profiling by array-CGH. Third, the Core will provide custom-designed tools and bioinformatics expertise for mining copy number data with integrated expression analyses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA127003-03
Application #
7879502
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
3
Fiscal Year
2009
Total Cost
$147,615
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Fadelu, Temidayo; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol 36:1112-1120
Doupé, David P; Marshall, Owen J; Dayton, Hannah et al. (2018) Drosophila intestinal stem and progenitor cells are major sources and regulators of homeostatic niche signals. Proc Natl Acad Sci U S A 115:12218-12223
Carr, Prudence R; Banbury, Barbara; Berndt, Sonja I et al. (2018) Association Between Intake of Red and Processed Meat and Survival in Patients With Colorectal Cancer in a Pooled Analysis. Clin Gastroenterol Hepatol :
Banerjee, Kushal K; Saxena, Madhurima; Kumar, Namit et al. (2018) Enhancer, transcriptional, and cell fate plasticity precedes intestinal determination during endoderm development. Genes Dev 32:1430-1442
Hamada, Tsuyoshi; Khalaf, Natalia; Yuan, Chen et al. (2018) Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol 16:1300-1306.e3
Hamada, Tsuyoshi; Zhang, Xuehong; Mima, Kosuke et al. (2018) Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status. Cancer Immunol Res 6:1327-1336
Pectasides, Eirini; Stachler, Matthew D; Derks, Sarah et al. (2018) Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov 8:37-48
Hazar-Rethinam, Mehlika; Kleyman, Marianna; Han, G Celine et al. (2018) Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer. Cancer Discov 8:417-427
Strickler, John H; Loree, Jonathan M; Ahronian, Leanne G et al. (2018) Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discov 8:164-173
Khalaf, Natalia; Yuan, Chen; Hamada, Tsuyoshi et al. (2018) Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies. Gastroenterology 154:1380-1390.e5

Showing the most recent 10 out of 590 publications